Kintara Therapeutics Inc (KTRA)

[undtrdr]

DelMar Pharmaceuticals, Inc. - "Modernizing Medicines: DelMar’s Strategic Edge for VAL-083 in Oncology"

NEW YORK, NY / ACCESSWIRE / January 8, 2016 / DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) today published a new blog post on The Chairman's Blog, written by the Company's Chief Executive Officer, Jeffrey Bacha. TheChairmansBlog.com is an exclusive online media publication that enables key executive officers a unique platform to share insights about their company and industry trends.

In his new blog, DelMar CEO Jeffrey Bacha explains how the Company is developing its lead drug candidate, VAL-083, for glioblastoma multiforme (GBM) by combining published preclinical and clinical data and a modern understanding of biologic pathways. Mr. Bacha describes how VAL-083 attacks brain tumors differently than current therapies and presents a potential new treatment paradigm for the majority of GBM patients who are underserved by current treatments. Finally, he provides his outlook for DelMar in 2016 in which he states, "DelMar has an exciting year in store in 2016, as we continue to build on the momentum of encouraging data with VAL-083 from our ongoing Phase II trial in refractory GBM and newly planned clinical studies in front-line GBM and NSCLC." Read the full blog post from Mr. Bacha on TheChairmansBlog.com
TheChairmansBlog.com/

About DelMar Pharmaceuticals, Inc.

DelMar Pharmaceuticals, Inc. was founded to develop and commercialize new cancer therapies in indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

About TheChairmansBlog.com

TheChairmansBlog.com is an exclusive, online media publication where publicly and privately held firms alike share insights about their companies and industries. TheChairmansBlog.com enables upper tier management to discuss issues that are of importance to their stakeholders, shareholders, and interested parties in an informal environment. www.thechairmansblog.com

SOURCE: TheChairmansBlog.com


https://www.accesswire.com/435397/DelMar-Pharmaceuticals-Inc-Modernizing-Medicines-DelMars-Strategic-Edge-for-VAL-083-in-Oncology